Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRegion Stockholm

About this trial

This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.

Eligibility criteria

Qualifiers

Age 18 years or older

Scheduled for clinical brain MRI with gadolinium contrast

Known or suspected brain metastases

Able to provide informed consent

Disqualifiers

Contraindications to MRI

Known allergy or contraindication to gadolinium-based contrast agents

Renal impairment (eGFR < 30 mL/min/1.73m²)

Pregnant or breastfeeding

Trial design

Treatments tested in this trial

  • Novel Gadolinium-Weighted MRI Sequence

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators